Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
:NMRA
NMRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.61 - $17.19
Previous CloseN/A
Volume2.95M
Average Volume (3M)2.13M
Market Cap
$268.50M
Enterprise Value-$88.18M
Total Cash (Recent Filing)$249.35M
Total Debt (Recent Filing)$938.00K
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Oct 29, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding161,747,920
10 Day Avg. Volume1,932,515
30 Day Avg. Volume2,129,203
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit551.11
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$8.00Price Target Upside381.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe announcement of a non-dilutive debt financing with K2 HealthVentures extends the cash runway into 2027 and potentially beyond.
Pharmacological AdvancementsNMRA-861 has demonstrated a potentially best-in-class pharmacological profile and has been safe and well tolerated in toxicology studies.
Product DevelopmentNeumora is not just focused on a single product, and other innovative pipeline assets like the V1aR antagonist and M4 programs can also create meaningful shareholder value.
Bears Say
Clinical HoldNMRA-266 was placed on clinical hold due to preclinical convulsion signals observed in rabbits.
Regulatory ChallengesRisks include the regulatory challenge as none of Neumora's products has been approved by the FDA.
Stock OverhangThe failure of KOASTAL-1 study and J&J discontinuing aticaprant development continues to be an overhang on the stock.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.61 and its highest was $17.19 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $268.50M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Oct 29, 2025 which is in 82 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.363 by $0.033.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 161,747,920 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.363. Following the earnings report the stock price went down -1.449%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (381.93% Upside)
$8.00 (381.93% Upside)
Blogger Sentiment
Bearish
NMRA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 613.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.12%
12-Months-Change
Fundamentals
Return on Equity
-79.05%
Trailing 12-Months
Asset Growth
-42.97%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. (NMRA) is a biotechnology company focused on developing precision medicines for neuropsychiatric and neurodegenerative disorders. The company leverages data-driven insights and neuroscience expertise to address the underlying biological pathways of brain diseases. Neumora's pipeline includes multiple investigational therapies targeting various neurological conditions, with a commitment to improving patient outcomes through innovative drug development.
NMRA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Neumora Therapeutics reported significant advancements in their pipeline and financial strength, positioning them well for future milestones. However, challenges in clinical study enrollment and increased net losses indicate hurdles that need addressing.View all NMRA earnings summariesNMRA Stock 12 Month Forecast
Average Price Target
$8.00
▲(381.93% Upside)
Technical Analysis
Ownership Overview
25.11% Insiders
5.67% Mutual Funds
1.41% Other Institutional Investors
64.75% Public Companies and
Individual Investors